麻黄附子细辛汤辅治阿尔茨海默病临床观察  

作　　者：周利渊 范晓玉 冯晓萍 

机构地区：[1]河南省登封市人民医院中医内科,河南登封452470

出　　处：《实用中医药杂志》2021年第5期854-855,共2页Journal of Practical Traditional Chinese Medicine

摘　　要：目的:观察麻黄附子细辛汤辅治阿尔茨海默病(AD)的效果。方法:98例采用随机数字奇偶法进行分组,两组均用多奈哌齐及美金刚治疗,观察组联合麻黄附子细辛汤治疗。结果:总有效率观察组93.88%,对照组77.55%,两组比较差异有统计学意义(P<0.05)。治疗后观察组蒙特利尔认知评估量表(MOCA)评分、日常生活自理能力评定表(ADL)评分较对照组高(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:麻黄附子细辛汤辅治AD疗效较好,且用药安全。Objective:To observe the effect of Mahuang Fuzi Xixin Decoction in the treatment of Alzheimer’s disease(AD). Methods: 98 cases were grouped by random number parity method. Both groups were treated with donepezil and memantine, and the observation group were treated with Mahuang Fuzi Xixin Decoction. Results: The total effective rate was 93.88% in the observation group and 77.55% in the control group. The difference between the two groups was statistically significant(P<0.05). After treatment, the scores of the Montreal Cognitive Assessment Scale(MOCA) and Activity of Daily Living Scale(ADL) of the observation group were higher than those of the control group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Mahuang Fuzi Xixin Decoction has a good effect in adjuvant treatment of AD, with safety.

关 键 词：阿尔茨海默病 麻黄附子细辛汤 认知功能 生活自理能力 

分 类 号：R249.27[医药卫生—中医临床基础]